Nkarta Inc (OQ:NKTX)
Business Focus: Bio Therapeutic Drugs
Sunny as of April 01, 2024
For the latest outlook, get the company report
You may also be interested in
Insider Filings
Latest 10 SEC Form 4 filings for NKTX*US within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
Loading...
Company News
Apr 08, 2024 12:55 ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ:
Apr 05, 2024 17:44 ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company’s possible violations of federal securities laws.
Valuation Ratios
Industry
Sector
Beta
0.85
--
--
Price to Sales - TTM
--
5.94
3.14
Price to Book - most recent quarter
1.29
2.19
2.08
Price to Cash Flow per share - TTM
--
17.66
13.73
Price to Free Cash Flow per share - TTM
--
16.96
23.65
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
